Company Encyclopedia
View More
name
Autolus Therapeutics
AUTL.US
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in United Kingdom and internationally. The company’s clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
1.946 T
AUTL.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking231/393
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-60.56%E
    • Profit Margin-439.68%E
    • Gross Margin-166.75%E
  • Growth ScoreB
    • Revenue YoY406.67%A
    • Net Profit YoY16.81%B
    • Total Assets YoY-20.01%E
    • Net Assets YoY-44.35%E
  • Cash ScoreB
    • Cash Flow Margin-22.74%D
    • OCF YoY406.67%A
  • Operating ScoreE
    • Turnover0.07E
  • Debt ScoreD
    • Gearing Ratio59.90%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    European Equities Traded in the US as American Depositary Receipts Higher in Wednesday Trading

    European equities traded in the US as ADRs rose 0.47% on the S&P Europe Select ADR Index. Leading gainers included Sequans Communications and Equinor, while Autolus Therapeutics and NuCana led decliners. Akari Therapeutics and Trinity Biotech also saw significant drops. MT Newswires cautions against unauthorized reproduction.

    fidelity·
    US
    AUTL
    +6.08%
    US
    AKTX
    0.00%
    US
    NCNA
    +4.48%
    fidelity·
    US
    AUTL
    +6.08%
    US
    AKTX
    0.00%
    US
    NCNA
    +4.48%

    Autolus Therapeutics Appoints Ryan Richardson to Board of Directors

    Autolus Therapeutics plc has appointed Ryan Richardson to its Board of Directors. Richardson has over 20 years of experience in strategy and corporate development, previously serving as Chief Strategy Officer at BioNTech. This appointment was announced via GlobeNewswire on December 01, 2025.

    Reuters·
    US
    AUTL
    +6.08%
    Reuters·
    US
    AUTL
    +6.08%

    The Nasdaq Biotechnology Index closed up nearly 1.4%, closely mirroring the performance of the Dow Jones Industrial Average. Among the constituent stocks, Esperion rose 16.09%, ARS Pharmaceuticals rose 15.50%, Anavex Life Sciences rose 12.34%, Personalis rose 12.31%, Autolus Therapeutics rose 12.10%, and Aura Biosciences rose 11.09%. AC Immune fell 5.84%, LENZ Therapeutics fell 6.51%, and Cullinan Oncology LLC fell 8.82%

    Wallstreetcn·
    US
    PSNL
    +3.05%
    US
    SPRY
    +4.40%
    US
    AURA
    +2.38%
    Wallstreetcn·
    US
    PSNL
    +3.05%
    US
    SPRY
    +4.40%
    US
    AURA
    +2.38%

    Autolus Therapeutics shares are trading higher after NICE issued draft guidance recommending AUCATZYL for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

    benzinga_article·
    US
    AUTL
    +6.08%
    benzinga_article·
    US
    AUTL
    +6.08%

    UK-developed leukaemia cell therapy to be offered on NHS

    Aucatzyl, a UK-developed cell therapy for B-cell acute lymphoblastic leukaemia, has been approved by NICE for NHS use in England and Wales. Developed by Autolus Therapeutics, this CAR-T treatment offers a personalized approach by modifying patients' T cells to fight cancer. Clinical trials show high remission rates, and it is recommended for patients aged 26 and over. The therapy is expected to launch imminently, with plans for Scotland access. NICE highlights its potential as a more effective, less toxic alternative to existing treatments.

    Pharmaceutical Technology·
    US
    AUTL
    +6.08%
    Pharmaceutical Technology·
    US
    AUTL
    +6.08%
    © 2025 Longbridge｜Disclaimer